» Articles » PMID: 39656086

Tissue-resident Natural Killer Cells Support Survival in Pancreatic Cancer Through Promotion of CDC1-CD8 T Activity

Abstract

The immunosuppressive microenvironment in pancreatic ductal adenocarcinoma (PDAC) prevents tumor control and strategies to restore anti-cancer immunity (i.e. by increasing CD8 T-cell activity) have had limited success. Here, we demonstrate how inducing localized physical damage using ionizing radiation (IR) unmasks the benefit of immunotherapy by increasing tissue-resident natural killer (trNK) cells that support CD8 T activity. Our data confirms that targeting mouse orthotopic PDAC tumors with IR together with CCR5 inhibition and PD1 blockade reduces E-cadherin positive tumor cells by recruiting a hypoactive NKG2D NK population, phenotypically reminiscent of trNK cells, that supports CD8 T-cell involvement. We show an equivalent population in human single-cell RNA sequencing (scRNA-seq) PDAC cohorts that represents immunomodulatory trNK cells that could similarly support CD8 T-cell levels in a cDC1-dependent manner. Importantly, a trNK signature associates with survival in PDAC and other solid malignancies revealing a potential beneficial role for trNK in improving adaptive anti-tumor responses and supporting CCR5 inhibitor (CCR5i)/αPD1 and IR-induced damage as a novel therapeutic approach.

Citing Articles

Transcriptional signature of CD56 NK cells predicts favourable prognosis in bladder cancer.

Khan M, Sedgwick A, Sun Y, Vivian J, Corbett A, Dolcetti R Front Immunol. 2025; 15:1474652.

PMID: 39877370 PMC: 11772185. DOI: 10.3389/fimmu.2024.1474652.

References
1.
Rand T, Cruikshank W, Center D, Weller P . CD4-mediated stimulation of human eosinophils: lymphocyte chemoattractant factor and other CD4-binding ligands elicit eosinophil migration. J Exp Med. 1991; 173(6):1521-8. PMC: 2190841. DOI: 10.1084/jem.173.6.1521. View

2.
Wang J, Saung M, Li K, Fu J, Fujiwara K, Niu N . CCR2/CCR5 inhibitor permits the radiation-induced effector T cell infiltration in pancreatic adenocarcinoma. J Exp Med. 2022; 219(5). PMC: 9006312. DOI: 10.1084/jem.20211631. View

3.
Bockorny B, Semenisty V, Macarulla T, Borazanci E, Wolpin B, Stemmer S . BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Nat Med. 2020; 26(6):878-885. DOI: 10.1038/s41591-020-0880-x. View

4.
Jin S, Guerrero-Juarez C, Zhang L, Chang I, Ramos R, Kuan C . Inference and analysis of cell-cell communication using CellChat. Nat Commun. 2021; 12(1):1088. PMC: 7889871. DOI: 10.1038/s41467-021-21246-9. View

5.
Siolas D, Morrissey C, Oberstein P . The Achilles' Heel of Pancreatic Cancer: Targeting pancreatic cancer's unique immunologic characteristics and metabolic dependencies in clinical trials. J Pancreatol. 2020; 3(3):121-131. PMC: 7595263. DOI: 10.1097/JP9.0000000000000052. View